نتایج جستجو برای: egfr mutation

تعداد نتایج: 315266  

2017
Ziwei Guo Fumei Yi Wencheng Yin Yu Zhang Qian Li Yangchun Gu Yu Xiao Baoshan Cao Liwen Ma Li Liang

BACKGROUND We explored correlations between the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, epidermal growth factor receptor (EGFR) mutation status, and prognosis. METHODS Data from 293 patients with lung adenocarcinoma were classified according to the new classification. Fisher's exact, χ2 , and log-rank te...

2016
Kuo-Hsuan Hsu Jeng-Sen Tseng Chih-Liang Wang Tsung-Ying Yang Chien-Hua Tseng Hsuan-Yu Chen Kun-Chieh Chen Chi-Ren Tsai Cheng-Ta Yang Sung-Liang Yu Kang-Yi Su Chong-Jen Yu Chao-Chi Ho Te-Chun Hsia Ming-Fang Wu Kuo-Liang Chiu Chien-Ming Liu Pan-Chyr Yang Jeremy J.W. Chen Gee-Chen Chang

Despite the advancement of epidermal growth factor receptor (EGFR) inhibitors in lung cancer therapy, it remains unclear whether EGFR mutation status in familial lung cancers is different from that of sporadic cases. In this multicenter retrospective study, we compared both the EGFR mutation frequency and patterns between familial and sporadic cases. The results explored that family history of ...

2016
Jacques De Grève Jan Van Meerbeeck Johan F. Vansteenkiste Lore Decoster Anne-Pascale Meert Peter Vuylsteke Christian Focan Jean-Luc Canon Yves Humblet Guy Berchem Benoit Colinet Danny Galdermans Lionel Bosquée Joanna Vermeij Alex Dewaele Caroline Geers Denis Schallier Erik Teugels

INTRODUCTION Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyrosine kinase domain mutations. Most data available pertain to Asian populations in which such mutations are more prevalent. We report on the long-term results of first-line treatment with erlotinib in Caucasi...

2014
Jeng-Sen Tseng Chih-Liang Wang Ming-Shyan Huang Chung-Yu Chen Cheng-Yu Chang Tsung-Ying Yang Chi-Ren Tsai Kun-Chieh Chen Kuo-Hsuan Hsu Meen-Hsin Tsai Sung-Liang Yu Kang-Yi Su Chih-Wei Wu Cheng-Ta Yang Yuh-Min Chen Gee-Chen Chang

INTRODUCTION Methods used for epidermal growth factor receptor (EGFR) mutation testing vary widely. The impact of detection methods on the rates of response to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-wild type (wt) lung adenocarcinoma patients is unknown. METHODS We recruited the Group-I patients to evaluate the efficacy of erlotinib in patients with EGFR-wt lung adenocarcinoma by eith...

Journal: :Anticancer research 2017
Kenichi Takeda Akira Yamasaki Tadashi Igishi Yuji Kawasaki Shizuka Ito-Nishii Hiroki Izumi Tomohiro Sakamoto Hirokazu Touge Masahiro Kodani Haruhiko Makino Masaaki Yanai Natsumi Tanaka Shingo Matsumoto Kunio Araki Hiroshige Nakamura Eiji Shimizu

BACKGROUND Chronic obstructive pulmonary disease is a smoking-related disease, and is categorized into the emphysema and airway dominant phenotypes. We examined the relationship between emphysematous changes and epidermal growth factor receptor (EGFR) mutation status in patients with lung adenocarcinoma. PATIENTS AND METHODS The medical records for 250 patients with lung adenocarcinoma were r...

2015
Nan Hu Ge Wang Yu-Hao Wu Shi-Feng Chen Guo-Dong Liu Chuan Chen Dong Wang Zhong-Shi He Xue-Qin Yang Yong He Hua-Liang Xiao Ding-De Huang Kun-Lin Xiong Yan Wu Ming Huang Zhen-Zhou Yang Leonardo Roever.

Epidermal growth factor receptor (EGFR) activating mutations are a predictor of tyrosine kinase inhibitor effectiveness in the treatment of non-small-cell lung cancer (NSCLC). The objective of this study is to build a model for predicting the EGFR mutation status of brain metastasis in patients with NSCLC. Observation and model set-up. This study was conducted between January 2003 and December ...

Journal: :Journal of hematology & oncology 2016
Shuhang Wang Shundong Cang Delong Liu

The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. These agents include osimertinib, rociletinib, HM61713, AS...

Journal: :Head & neck 2008
Ilona Schwentner Martina Witsch-Baumgartner Georg M Sprinzl Jens Krugmann Alexandar Tzankov Siegfried Jank Heinz Zwierzina Judith Loeffler-Ragg

BACKGROUND Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) are involved in tumorigenesis and response to targeted therapies in distinct cancer types. Squamous cell carcinomas of the head and neck (HNSCC) show an incidence of EGFR mutations varying from 7% in Asians to 0% to 4% in white patients. Mutational screening predominantly focuses on the ana...

Journal: :The European respiratory journal 2008
S-G Wu C-H Gow C-J Yu Y-L Chang C-H Yang Y-C Hsu J-Y Shih Y-C Lee P-C Yang

Malignant pleural effusions (MPEs) are often observed in lung cancer, especially adenocarcinoma. Epidermal growth factor receptor (EGFR) gene mutations are usually detected in lung adenocarcinoma. The purpose of the present study was to investigate the EGFR mutation rate in MPEs of lung adenocarcinoma. Between June 2005 and December 2006, 136 MPEs from lung adenocarcinoma were collected for EGF...

2016
Hirotaka Hoshi Gen Hiyama Kosuke Ishikawa Kiyoshi Inageda Jiro Fujimoto Ai Wakamatsu Takushi Togashi Yoshifumi Kawamura Nobuhiko Takahashi Arisa Higa Naoki Goshima Kentaro Semba Shinya Watanabe Motoki Takagi

Epidermal growth factor receptor (EGFR) overexpression and EGFR-mediated signaling pathway dysregulation have been observed in tumors from patients with various cancers, especially non-small cell lung cancer. Thus, several anti-EGFR drugs have been developed for cancer therapy. For patients with known EGFR activating mutations (EGFR exon 19 in-frame deletions and exon 21 L858R substitution), tr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید